Previous 10 | Next 10 |
home / stock / uthr / uthr articles
United Therapeutics (NASDAQ:UTHR) has outperformed the market over the past 20 years by 9.58% on an annualized basis producing an average annual re...
Perrigo Company plc (NYSE: PRGO) reported adjusted earnings of 29 cents per share in the first quarter of 2024, beating the Zacks Consensus Estimat...
On Wednesday, United Therapeutics Corporation (NASDAQ:UTHR) reported first-quarter sales of $677.7 million, up 34% year over year, b...
Wednesday, United Therapeutics Corporation (NASDAQ:UTHR) initiated legal action against the FDA, claiming that the FDA wrongly allowed&nb...
United Therapeutics Corporation (NASDAQ: UTHR) is in a patent dispute with Liquidia Corp (NASDAQ: LQDA). While the company’s franchise positi...
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgr...
Liquidia Corp (NASDAQ: LQDA) stock jumped after a win in a patent dispute with United Therapeutics Corporation (NASDAQ: UT...
United Therapeutics (NASDAQ:UTHR) has announced an acquisition of Miromatrix Medical (NASDAQ:MIRO) that is expected to be completed in Q4 of 2023. ...
United Therapeutics Corporation (NASDAQ: UTHR) has agreed to acquire Miromatrix Medical Inc (NASDAQ: MIRO) for $3.25 per share in ca...
News, Short Squeeze, Breakout and More Instantly...
United Therapeutics Corporation Company Name:
UTHR Stock Symbol:
NASDAQ Market:
United Therapeutics Corporation Website:
A look at the top 10 most actives in the United States Aptevo Therapeutics Inc. (APVO) rose 45.1% to $0.486 on volume of 64,992,551 shares Verb Technology Company Inc. (VERB) rose 3.5% to $0.1205 on volume of 54,410,242 shares NVIDIA Corporation (NVDA) fell 4.4% to $120.752 on volume of 4...
2024-07-11 06:30:06 ET Morgan Stanley analyst issues EQUAL-WEIGHT recommendation for UTHR on July 11, 2024 04:53AM ET. The previous analyst recommendation was Overweight. UTHR was trading at $329.25 at issue of the analyst recommendation. The overall analyst consensus : ...
Over 100,000 patients in the United States have IPF, with two approved therapies available that only slow the course of disease progression Top line data expected in the second half of 2025 United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation, announ...